• Aethlon Medical posted a net loss attributable to common stockholders of $7.15 million, narrowing from $13.39 million a year earlier.
• Operating loss improved to $7.29 million as operating expenses fell 21.9% to $7.29 million.
• Other income swung to $142,162 from other expense a year earlier, reflecting interest income on cash balances.
• Cash and cash equivalents totaled $5.03 million at March 31, 2026; it raised about $1.85 million in net proceeds via an at-the-market program after year-end.
• Entered the third and final dosing cohort in its Australian oncology study; the first Cohort 3 participant completed three Hemopurifier treatments without device deficiencies or immediate complications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80004) on June 10, 2026, and is solely responsible for the information contained therein.